BioStock: Patents and study in focus for Promore Pharma

When Promore Pharma looks back on 2022, it can look back on an eventful year with several important milestones achieved. 2023 does not promise to be any less hectic, in November the company announced that the results from the PHSU05 study with ensereptide for scarring on skin are expected to be available as early as April 2023. BioStock talked to CEO Jonas Ekblom about the past year and what awaits Promore Pharma.

Read the full article about Promore Pharma at biostock.se:

https://www.biostock.se/en/2023/03/patents-and-study-in-focus-for-promore-pharma/

This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/en/